Literature DB >> 30149783

A Case of Mercury Toxicity Complicated by Acute Inflammatory Demyelinating Polyneuropathy.

Stacey Evans1, Jeffrey Smith1, Elena Caron1.   

Abstract

A 13-year-old African American male presented with 2 months of subacute altered mental status, ptosis, areflexia, disordered gait, constipation, weight loss, abdominal and testicular pain, and hyperhidrosis. Initial workup at our facility was unrevealing until elevated serum mercury level was detected. Diagnosis of mercury toxicity was confirmed, and chelation therapy with succimer was started. After beginning succimer, the patient developed acute-onset weakness and was diagnosed with acute inflammatory demyelinating polyneuropathy. Supportive studies included elevated cerebrospinal fluid protein and acquired demyelinating polyneuropathy on nerve conduction study. He responded well to treatment with intravenous immunoglobulin and returned to his baseline state of health. Although there is a known association between mercury toxicity and axonal neuropathy, there is only 1 other case report of acute inflammatory demyelinating polyneuropathy in the setting of mercury toxicity. The nature of the correlation between these 2 entities in our case remains unclear.

Entities:  

Keywords:  Guillain-Barre syndrome; mercury poisoning; neuropathy

Mesh:

Substances:

Year:  2018        PMID: 30149783     DOI: 10.1177/0883073818790408

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Mercury in the human adrenal medulla could contribute to increased plasma noradrenaline in aging.

Authors:  Roger Pamphlett; Stephen Kum Jew; Philip A Doble; David P Bishop
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.379

Review 2.  Mercury as a cause of membranous nephropathy and Guillain-Barre syndrome: case report and literature review.

Authors:  Chen Yawei; Sun Jing; Shi Wenju; Li Yupeng; Zhang Ping; Han Liping
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.